Literature DB >> 1934265

Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon.

R J Turesky1, N P Lang, M A Butler, C H Teitel, F F Kadlubar.   

Abstract

The metabolic activation of the food-borne rodent carcinogens 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole (Glu-P-1) was compared with that of the known human carcinogen 4-aminobiphenyl (ABP), using human liver microsomes, human and rat liver cytosols, and human colon cytosol. All of these aromatic amines were readily activated by N-hydroxylation with human liver microsomes (2.3-5.3 nmol/min/mg protein), with PhIP and ABP exhibiting the highest rates of cytochrome P450IA2-dependent N-oxidation, followed by MeIQx, IQ and Glu-P-1. In contrast, while ABP and 2-aminofluorene were readily N-acetylated (1.7-2.3 nmol/min/mg protein) by the polymorphic human liver cytosolic N-acetyltransferase, none of the heterocyclic amines were detectable as substrates (less than 0.05 nmol/min/mg protein). Likewise, only low activity was observed (0.11 nmol/min/mg protein) for the N-acetylation of p-aminobenzoic acid, a selective substrate for the human monomorphic liver N-acetyltransferase. The radiolabeled N-hydroxy (N-OH) arylamine metabolites were synthesized and their reactivity with DNA was examined. Each derivative bound covalently with DNA at neutral pH (7.0), with highest levels of binding observed for N-OH-IQ and N-OH-PhIP. Incubation at acidic pH (5.0) resulted in increased levels of DNA binding, suggesting formation of reactive arylnitrenium ion intermediates. These N-OH arylamines were further activated to DNA-bound products by human hepatic O-acetyltransferase. Acetyl coenzyme A (AcCoA)-dependent, cytosol-catalyzed DNA binding was greatest for N-OH-ABP and N-OH-Glu-P-1, followed by N-OH-PhIP, N-OH-MeIQx and N-OH-IQ; and both rapid and slow acetylator phenotypes were apparent. Rat liver cytosol also catalyzed AcCoA-dependent DNA binding of the N-OH arylamines; and substrate specificities were comparable to human liver, except that N-OH-MeIQx and N-OH-PhIP gave relatively higher and lower activities respectively. Human colon cytosols likewise displayed AcCoA-dependent DNA binding activity for the N-OH substrates. Metabolic activity was generally lower than that found with the rapid acetylator liver cytosols; however, substrate specificity was variable and phenotypic differences in colon O-acetyltransferase activity could not be readily discerned. This may be due, at least in part, to the varied contribution of the monomorphic acetyltransferase, which would be expected to participate in the enzymatic acetylation of some of these N-OH arylamines.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934265     DOI: 10.1093/carcin/12.10.1839

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  80 in total

Review 1.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Identification of carcinogen DNA adducts in human saliva by linear quadrupole ion trap/multistage tandem mass spectrometry.

Authors:  Erin E Bessette; Simon D Spivack; Angela K Goodenough; Tao Wang; Shailesh Pinto; Fred F Kadlubar; Robert J Turesky
Journal:  Chem Res Toxicol       Date:  2010-07-19       Impact factor: 3.739

3.  The C8-2'-deoxyguanosine adduct of 2-amino-3-methylimidazo[1,2-d]naphthalene, a carbocyclic analogue of the potent mutagen 2-amino-3-methylimidazo[4,5-f]quinoline, is a block to replication in vitro.

Authors:  Plamen P Christov; Goutam Chowdhury; Craig A Garmendia; Feng Wang; James S Stover; C Eric Elmquist; Albena Kozekova; Karen C Angel; Robert J Turesky; Michael P Stone; F Peter Guengerich; Carmelo J Rizzo
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

4.  1H nuclear magnetic resonance spectroscopy-based studies of the metabolism of food-borne carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline by human intestinal microbiota.

Authors:  Christèle Humblot; Bruno Combourieu; Marja-Liisa Väisänen; Jean-Pierre Furet; Anne-Marie Delort; Sylvie Rabot
Journal:  Appl Environ Microbiol       Date:  2005-09       Impact factor: 4.792

5.  Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate.

Authors:  E Banoglu; G G Jha; R S King
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

6.  Effect of rapid human N-acetyltransferase 2 haplotype on DNA damage and mutagenesis induced by 2-amino-3-methylimidazo-[4,5-f]quinoline (IQ) and 2-amino-3,8-dimethylimidazo-[4,5-f]quinoxaline (MeIQx).

Authors:  Kristin J Metry; Jason R Neale; Mark A Doll; Ashley L Howarth; J Christopher States; W Glenn McGregor; William M Pierce; David W Hein
Journal:  Mutat Res       Date:  2009-12-11       Impact factor: 2.433

7.  Vegetable and animal products as determinants of colon cancer risk in Dutch men and women.

Authors:  E Kampman; D Verhoeven; L Sloots; P van 't Veer
Journal:  Cancer Causes Control       Date:  1995-05       Impact factor: 2.506

Review 8.  Interplay between heterocyclic amines in cooked meat and metabolic phenotype in the etiology of colon cancer.

Authors:  P Vineis; A McMichael
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

9.  Capturing labile sulfenamide and sulfinamide serum albumin adducts of carcinogenic arylamines by chemical oxidation.

Authors:  Lijuan Peng; Robert J Turesky
Journal:  Anal Chem       Date:  2012-12-28       Impact factor: 6.986

10.  Biomonitoring of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and its carcinogenic metabolites in urine.

Authors:  Jean-Marie Fede; Anup P Thakur; Nigel J Gooderham; Robert J Turesky
Journal:  Chem Res Toxicol       Date:  2009-06       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.